- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06210594
Staph Intervention for Effective Local Defense (SHIELD)
SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults
Study Overview
Status
Conditions
Detailed Description
Staphylococcus aureus (SA) is a common cause of skin and soft tissue infections (SSTI) and invasive infections in the United States (US). Infections caused by methicillin-resistant SA (MRSA) are of particular concern because MRSA is harder to treat and associated with significant costs to healthcare systems and patients. The White Mountain Apache (WMA) Tribe experiences a higher burden of SA and MRSA infections than the general US population. Most cases of invasive SA occurred among adults with underlying conditions and led to significant morbidity.
SA carriage is an important factor for development of SA infections. When individuals or the household contacts have recurrent SA infections, the use of antimicrobial or antiseptic agents to suppress or eliminate SA carriage (so called "decolonization") may be recommended to help prevent infection. While there are several regimens available to suppress carriage, each has limitations (e.g., potential antimicrobial resistance following repeated use of mupirocin antibiotic ointment, lack of access to a bathtub or reliable water supply for bleach baths). These interventions are typically used over a short period of time (e.g., one-time administration over 5-10 days). Re-acquisition of carriage in the months following completion of the carriage suppression regimen is common. Use of the standard approaches to SA carriage suppression in the WMA community has been inconsistent and has been insufficient to control SA disease. New approaches are urgently needed.
In formative research conducted by the study team, in-depth interviews and focus group discussions were conducted with healthcare providers and community members to understand the culture and context of tribal communities as related to SA infections, disease, and prevention. The researchers found that there are gaps in community knowledge about SA as a cause of skin infections and how to prevent an infection. When asked about preferred method of intervention to reduce SA carriage, participants indicated a preference for the antiseptic nasal spray (daily use) and antiseptic body wash (regular use), which were easily administered and could be incorporated into a daily routine.
In this study, the investigators will conduct an open-label randomized controlled trial to determine the feasibility, acceptability, and efficacy of a carriage suppression regimen in reducing the prevalence of SA carriage and SA infections among adults at high risk of SA infections who are currently carrying SA on the skin. Following informed consent, participants will be randomized in a ratio of 1:1 to either: A) education about SA and receipt of household supplies to reduce SA transmission in the home plus use of a nasal antibiotic twice daily for 5 days then maintenance with an antiseptic regimen (N = 50; Group A); or B) education/household supplies alone (N = 50; Group B). The antiseptic regimen will consist of twice daily Nozin nasal antiseptic plus chlorhexidine gluconate wash three times a week. Participants assigned to Group A will continue the antiseptic regimen for 4 months. All participants will be followed for 4 months.
Study visits will occur at baseline (Day 0) and Days 14, 30, 60, 90, and 120. At each visit, a questionnaire will be administered and swabs will be collected at common carriage sites on the body (anterior nares, oropharynx, and groin). Group A will also receive reminder text messages or phone calls at a frequency of choice (e.g., once per day or once per week). After the Day 0 and Day 120 visits, the participant's medical record will be reviewed to document relevant medical history and outpatient and inpatient visits for SSTI and SA-related infections.
A home visit will be scheduled after Day 0 to collect environmental swabs at frequent hand-contact sites (e.g., bedroom, living room, bathroom) and swabs from indoor pet cats and dogs (e.g., dorsal fur and skin of groin). Household members will also be recruited to complete a brief questionnaire and sample collection (anterior nares, oropharynx, and groin).
A qualitative assessment will be conducted in a subset of index participants (n=6-10) in Group A to assess adherence and acceptability of the prevention regimen. Participants will be chosen using purposive sampling to represent a range of reported adherence at the D60 visit and invited to provide informed consent. The qualitative assessment will consist of one in-depth interview at the endpoint (4 months).
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Monica Pilewskie, MSPH
- Phone Number: 928-338-5215
- Email: mpilews1@jhu.edu
Study Contact Backup
- Name: Laura Hammitt, MD
- Phone Number: 410-955-6931
- Email: lhammitt@jhu.edu
Study Locations
-
-
Arizona
-
Whiteriver, Arizona, United States, 85941
- Recruiting
- Whiteriver Center for Indigenous Health
-
Contact:
- Monica Pilewskie, MSPH
- Phone Number: 928-338-5215
- Email: mpilews1@jhu.edu
-
Principal Investigator:
- Laura Hammitt, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Native American adult living on or adjacent to the WMA Tribal lands
- 18 years of age and older
- Lab-confirmed SA carriage at time of enrollment
- Ability to provide written informed consent
- Ability to comply with follow-up activities
- Risk factor for SA-associated infection: Diagnosed with diabetes OR body mass index ≥30 OR documented SSTI or SA infection in the past 3 years
Exclusion Criteria:
- Immediate family member of study staff
- Allergy to citrus or any ingredient in Nozin, Hibiclens, or mupirocin
- Without a permanent home (e.g., living in a group home, shelter, or is unhoused)
- Use of antibiotics within 30 days prior to the first study visit (time-limited)
- Current SA infection (time-limited)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Education + Household supplies + Nasal antibiotic + Antiseptic regimen
Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels) plus use of a nasal antibiotic (mupirocin) twice daily for 5 days then maintenance with an antiseptic regimen (Nozin twice daily plus chlorhexidine gluconate wash 3 times per week)
|
Education/household supplies + antibiotic + antiseptic regimen
Other Names:
Education/household supplies
|
Active Comparator: Education + Household supplies
Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels).
|
Education/household supplies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of SA carriage
Time Frame: 4 months after randomization
|
Compare SA carriage prevalence in the nose, throat, and skin (any site) between arms.
|
4 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and Acceptability
Time Frame: 4 months
|
Proportion adhering to intervention.
|
4 months
|
Feasibility and Acceptability as assessed by in depth interviews
Time Frame: 4 months
|
Assess the feasibility and acceptability qualitatively through in-depth interviews (with a subset of participants).
|
4 months
|
Incidence of SSTI
Time Frame: 4 months
|
Compare the incidence of skin and soft tissue infections (all cause) between arms.
|
4 months
|
Characterize SA isolates
Time Frame: 4 months
|
Characterize SA isolates, including lineages (proportion belonging to each clonal complex) and antimicrobial resistance (proportion MRSA), during follow-up in both arms.
|
4 months
|
Confirmed SA infection
Time Frame: 4 months
|
Compare the incidence of lab-confirmed SA infection (all types and SSTI separately) between arms.
|
4 months
|
Prevalence of SA carriage in index participants, household members, indoor pets, and household surfaces
Time Frame: Baseline, day 14, day 30, day 60, day 90, day 120
|
Describe baseline prevalence of SA carriage in index patients, household members, indoor pets, and household surfaces, and longitudinal prevalence in index participants, and compare between arms.
|
Baseline, day 14, day 30, day 60, day 90, day 120
|
Adverse events
Time Frame: 4 months
|
The proportion of participants with adverse events (e.g., dry skin) and compare between arms.
|
4 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Laura Hammitt, MD, Johns Hopkins Bloomberg School of Public Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Staphylococcal Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Disinfectants
- Mupirocin
- Chlorhexidine
- Chlorhexidine gluconate
Other Study ID Numbers
- IRB00027090
- 5S06GM142120 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus Infection
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Washington University School of MedicineActive, not recruitingStaphylococcus Aureus | Skin and Subcutaneous Tissue Bacterial Infections | MRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
University of PennsylvaniaChildren's Hospital of Philadelphia; Milton S. Hershey Medical Center; Pennsylvania...CompletedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Massachusetts General HospitalTerminatedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionKorea, Republic of
-
University College, LondonKing's College London; Rambam Health Care Campus; University of Melbourne; Menzies... and other collaboratorsNot yet recruitingSepsis | Staphylococcus Aureus Infection | Bloodstream Infection | Staphylococcus Aureus Bacteremia | Sepsis Bacterial | Staphylococcus Aureus Septicemia | Staph Sepsis
-
CAMC Health SystemUnknownMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
B. Braun Medical SATerminatedMRSA - Methicillin Resistant Staphylococcus Aureus Infection | MRSA ColonizationSpain
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore
-
R. Stephen Rankin, M.D.UnknownCommunity-acquired Methicillin-resistant Staphylococcus Aureus InfectionUnited States
Clinical Trials on Mupirocin + Nozin + chlorhexidine gluconate
-
Montefiore Medical CenterCompleted
-
Johns Hopkins UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedStaph Aureus Colonization | Staph Aureus InfectionUnited States
-
Chiang Mai UniversityHealth Systems Research Institute, ThailandUnknownPeritoneal Dialysis | End Stage Renal DiseaseThailand
-
Lundquist Institute for Biomedical Innovation at...Kaiser PermanenteCompletedMethicillin Resistant Staphylococcus Aureus Skin InfectionsUnited States
-
Johns Hopkins UniversityRobert Wood Johnson FoundationCompleted
-
University of California, IrvineUniversity of California, Davis; University of California, San Francisco; University...RecruitingSurgical Site InfectionUnited States
-
University of TennesseeUnited States Department of DefenseCompleted
-
Clinical Directors NetworkPatient-Centered Outcomes Research Institute; Rockefeller UniversityUnknownRecurrence | Staphylococcal Skin Infections | Antibiotic Resistance | Methicillin-Resistant Staphylococcus AureusUnited States
-
University of MilanCompleted
-
Washington University School of MedicineCompletedThe Natural History of Community-Associated MRSA Infections and Decolonization Strategies (StLStaRS)Furunculosis | Staphylococcus Aureus | Staphylococcal Skin Infections | AbscessesUnited States